Suit to Test Rights of Physicians to Receive Info on Off-Label Drug Use

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

WASHINGTON--The Washington Legal Foundation (WLF), a public interest group, has claimed that the FDA violated the First Amendment rights of physicians by denying them access to information about the off-label use of certain oncologic drugs.

WASHINGTON--The Washington Legal Foundation (WLF), a public interestgroup, has claimed that the FDA violated the First Amendment rightsof physicians by denying them access to information about theoff-label use of certain oncologic drugs.

WLF's suit arises from an action taken by the FDA that preventedBristol-Myers Squibb Co.from giving physicians complimentary copiesof The Chemotherapy Sourcebook, edited by Michael Perry, and chaptersfrom Cancer: Principles and Practice of Oncology, by Vincent DeVita,Samuel Hellman, and Steven Rosenberg.

Federal Judge Royce Lamberth denied the FDA's motion to dismissthe suit, thus clearing the way for a trial, which will be thefirst constitutional test of the agency's criteria to discouragewhat it views as improper promotion of drugs by means of distributionof legitimate medical educational material.

Recent Videos
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Related Content